Cao XY, Jia ZF, Jin MS, Cao DH, Kong F, Suo J, Jiang J. Serum pepsinogen II is a better diagnostic marker in gastric cancer. World J Gastroenterol 2012; 18(48): 7357-7361 [PMID: 23326145 DOI: 10.3748/wjg.v18.i48.7357]
Corresponding Author of This Article
Jing Jiang, MD, PhD, Division of Clinical Epidemiology, Jilin University First Hospital, 71Xin min Street, Changchun 130021, Jilin Province, China. ccmzc32jdyycao@yahoo.com.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xue-Yuan Cao, Jian Suo, Department of Gastrointestinal Surgery, Jilin University First Hospital, Changchun 130021, Jilin Province, China
Zhi-Fang Jia, Dong-Hui Cao, Fei Kong, Jing Jiang, Division of Clinical Epidemiology, Jilin University First Hospital, Changchun 130021, Jilin Province, China
Mei-Shan Jin, Division of Pathology, Jilin University First Hospital, Changchun 130021, Jilin Province, China
ORCID number: $[AuthorORCIDs]
Author contributions: Cao XY and Jiang J designed the study and carried out most of the study; Cao XY, Jia ZF and Jiang J wrote the first draft of the manuscript; Jin MS analyzed the pathological data; Cao DH and Kong F collected patients’ clinical information; Jiang J performed statistical analysis; and Suo J provided valuable suggestions in the preparation of the manuscript.
Supported by National Natural Science Foundation of China, No. 30972476 and 81072369
Correspondence to: Jing Jiang, MD, PhD, Division of Clinical Epidemiology, Jilin University First Hospital, 71Xin min Street, Changchun 130021, Jilin Province, China. ccmzc32jdyycao@yahoo.com.cn
Received: September 24, 2012 Revised: November 6, 2012 Accepted: November 24, 2012 Published online: December 28, 2012
Abstract
AIM: To investigate screening makers for gastric cancer, we assessed the association between gastric cancer and serum pepsinogens (PGs).
METHODS: The subjects comprised 450 patients with gastric cancer, 111 individuals with gastric atrophy, and 961 healthy controls. Serum anti-Helicobacter pylori (H. pylori) immunoglobulin G (IgG), PGIand PG II were detected by enzyme-linked immunosorbent assay. Gastric atrophy and gastric cancer were diagnosed by endoscopy and histopathological examinations. Odds ratios and 95%CIs were calculated using multivariate logistic regression.
RESULTS: Rates of H. pylori infection remained high in Northeastern China. Rates of H. pylori IgG positivity were greater in the gastric cancer and gastric atrophy groups compared to the control group (69.1% and 75.7% vs 49.7%, P < 0.001). Higher levels of PG II (15.9 μg/L and 13.9 μg/L vs 11.5 μg/L, P < 0.001) and lower PGI/PG II ratio (5.4 and 4.6 vs 8.4, P < 0.001) were found in patients with gastric cancer or gastric atrophy compared to healthy controls, whereas no correlation was found between the plasma PGIconcentration and risk of gastric cancer (P = 0.537). In addition, multivariate logistic analysis indicated that H. pylori infection and atrophic gastritis were independent risk factors for gastric cancer. Lower plasma PGI/PG II ratio was associated with higher risks of atrophy and gastric cancer. Furthermore, plasma PG II level significantly correlated with H. pylori-infected gastric cancer.
CONCLUSION: Serum PG II concentration and PGI/PG II ratio are potential biomarkers for H. pylori-infected gastric disease. PG II is independently associated with risk of gastric cancer.
Citation: Cao XY, Jia ZF, Jin MS, Cao DH, Kong F, Suo J, Jiang J. Serum pepsinogen II is a better diagnostic marker in gastric cancer. World J Gastroenterol 2012; 18(48): 7357-7361
Gastric cancer remains the third leading cause of cancer death in China[1]. Helicobacter pylori (H. pylori) and gastric atrophy have both been identified as etiological factors for gastric cancer. However, screening and eradication of H. pylori in the general population is not advised because the cost of programs outweighs the modest effect on reduced incidences of gastric cancer. Therefore, identification of patients with the early stage gastric cancer could improve treatment and survival. Gastric atrophy, the precancerous lesion of gastric cancer, can be diagnosed by histological examination, and measurement of serum concentration of pepsinogens (PGs). Levels of two biochemically and immunologically distinct types, PGIand PG II, indicate different status of gastric mucosa. Serum PG level screening can be carried out at low cost in countries with high and moderate incidences of gastric cancer, such as Japan and China[2].
Most studies have demonstrated that low concentrations of PGIand low PGI/PG II ratios in the serum or plasma are indicators of atrophic gastritis, which are linked with elevated gastric cancer risk[3-5]. However, few studies have assessed correlations between PG II and gastric cancer risk[6,7]. It is well known that H. pylori infection leads to development of both atrophic gastritis and gastric cancer. Detection of serum anti-H. pylori immunoglobulin G (IgG) antibodies and screening for gastric atrophy and gastric cancer at an early stage are important for clinical assessments and interventions[8,9]. Absence of data on H. pylori infection and serum PG levels are available in large epidemiological surveys. To identify relationships between gastric mucosal lesions and serum PG levels, we carried out an assessment of PGIand PG II levels, PGI/PG II ratio and risk of gastric cancer in a cross-sectional study.
MATERIALS AND METHODS
Study participants
Four hundred and fifty patients with gastric cancer were selected from the Department of Gastric and Colorectal Surgery, and Department of Gastroenterology, First Hospital of Jilin University, from 2008 to 2010. All gastric cancer patients underwent tumor resection with histologically confirmed diagnosis of gastric adenocarcinoma. From 2009 to 2010, gastric atrophy cases and healthy controls were recruited from the check-up center of the same hospital. The subjects were of Han descent from the Changchun region. A total 1109 subjects (644 male and 465 female, aged 35-80 years) participated in the study. Gastric atrophy was diagnosed by endoscopy and histopathological examinations. Written informed consent was obtained from all subjects and the study protocol was approved by the Ethics Committee of the First Hospital, Jilin University.
Sampling and determination of serum
Fasting blood was taken for all participants and serum was collected and stored at -80 °C. In the gastric cancer group, the samples were collected before surgery. Serum PGIand PG II levels were measured by enzyme-linked immunosorbent assay (ELISA) (Biohit ELISA kit, Biohit, Helsinki, Finland). Serum IgG antibodies to H. pylori were detected by ELISA using an H. pylori-IgG ELISA kit (Biohit). The antibody titers were defined by optical density values according to the manufacturer’s protocol and titers higher than the cutoff value of 30 EIU were considered as positive for H. pylori infection. The quality control sample showed a coefficient of variation (CV) of 6.4%. For the pooled plasma samples the CV was 4.5%. According to the Chinese guidelines for diagnosis, patients are considered to have atrophic gastritis if PGIis ≤ 82.3 μg/L and PGI/PG II ratio is ≤ 6.05[10]. The quality control samples showed CVs of 4.5%, 4.3% and 4.7% for H. pylori, PGIand PG II, respectively. All suspected cases with gastric atrophy by serum screening were re-determined by endoscopic biopsy and histological examinations.
Statistical analysis
The data did not fit a normal distribution, therefore, we used the Wilcoxon rank sum test to compare medians (quartiles) between the two groups. The χ2 test was used to compare multiple sample rates. Non-conditional logistic regression analysis was used to calculate the odds ratio of risk-related factors for gastric cancer and its 95%CI. Two tailed P values < 0.05 were considered as statistically significant. All statistical analysis were carried out by SPSS version 18 software.
RESULTS
There were 450 patients with gastric cancer (324 male and 126 female, aged 35-80 years). Sixty-four cases were categorized as tumor-node-metastasis stageI(14.2%), 182 as stage II (40.4%), 145 as stage III (32.2%), and 59 as stage IV (13.1%). Among the 1109 participants, 148 individuals were screened for gastric atrophy using serum PG examination and 111 patients were confirmed with gastric atrophy by biopsy and histopathological examinations. Seventeen subjects were diagnosed with pseudopositive gastric atrophy and excluded from the study; 20 participants who rejected endoscopic examinations were also excluded. The remaining 961 individuals were included in the control group. The mean age was older in the gastric cancer group than in the gastric atrophy and control groups. The subject characteristics are summarized in Table 1.
Table 1 Comparison of Helicobacter pylori infection between gastric cancer and control groups.
Gastric cancer group (%)
Gastric atrophy group (%)
Control group (%)
P value
No.
450
111
961
H. pylori infection
Negative
139 (30.9)
27 (24.3)
483 (50.3)
Positive
311 (69.1)
84 (75.7)
478 (49.7)
< 0.001
Sex
Male
324 (72.0)
66 (59.5)
564 (58.7)
< 0.001
Female
126 (28.0)
45 (40.5)
397 (41.3)
Age
< 45 yr
38 (8.4)
20 (18.0)
285 (29.7)
< 0.001
45-65 yr
240 (53.3)
81 (73.0)
607 (63.2)
> 65 yr
172 (38.2)
10 (9.0)
69 (7.2)
H. pylori infection
H. pylori-positive rates in the gastric cancer and gastric atrophy groups were significantly higher compared to those in the control group (69.1% and 75.7% vs 49.7%, P < 0.001). The H. pylori infection rates were higher in the 45-65 years group compared to those aged < 45 years or > 65 years. Among the 450 gastric cancer patients, H. pylori infection rate was higher in those with stageIand stage II disease, compared to those with stage III and IV disease (73.6% vs 63.7%, P = 0.02). There were no correlations found between H. pylori infection and pathological type, tumor site, and differentiation of tumors (well-differentiated 50%, mild differentiation 69.8%, and poor differentiation 72.9%, P = 0.47).
PG levels
The median (interquartile range; IQR) PGIand PG II levels, and the ratio of PGI/PG II in the controls were 92.6 μg/L (75.0-116.1), 11.5 μg/L (7.1-18.4), and 8.4 μg/L (6.1-11.1), respectively. PG II level in the gastric cancer group was significantly higher than that in the control group (P < 0.001), whereas the PGI/PG II ratio showed a marked decline (P < 0.001) (Table 2). However, no statistically significant difference was found in PGIlevel between the two groups (P = 0.532). In the control group, a higher PGIlevel was detected in patients with H. pylori infection compared to H. pylori-negative patients (median: 99 vs 78.9 μg/L, P < 0.001).
Table 2 Comparison of pepsinogen levels between gastric cancer, gastric atrophy and control groups.
Gastric cancer group
Gastric atrophy group
Control group
P value (cancer vs control)
P value (atrophy vs control)
PGI(μg/L)
93.2 (49.8-147.3)
64.0 (52.3-75.3)
92.6 (75.0-116.1)
0.537
< 0.001
PG II (μg/L)
15.9 (9.0-28.0)
13.9 (11.9-16.9)
11.5 (7.1-18.4)
< 0.001
< 0.001
PGI/PGII
5.4 (3.5-8.1)
4.6 (3.6-5.3)
8.4 (6.1-11.1)
< 0.001
< 0.001
Median (IQR) levels of PGIand PG II, and PGI/PG II ratio were 94.4 µg/L (38.9-148.8), 13.3 μg/L (7.7-22.5) and 6.2 (3.5-10.0) μg/L for 139 H. pylori-negative gastric cancer patients, respectively. Median (IQR) levels of PGIand PG II, and PGI/PG II ratio were 92.2 μg/L (53.0-145.3), 18.4 μg/L (10.4-30.0) and 5.1 μg/L (3.5-7.2), respectively, for 311 H. pylori-positive gastric cancer patients. The difference in PG II level and PGI/PG II ratio was significant (P = 0.01) between H. pylori (-) and H. pylori (+) subjects. However, no significant difference in PGIconcentrations was found between H. pylori (-)and H. pylori (+) cases in the gastric cancer group (92.2 μg/L vs 94.4 μg/L, P = 0.96) (Table 3). In addition, serum PGIconcentration was significantly lower in patients with stage III and IV tumors compared to stageIand II (Table 4).
Table 3Helicobacter pylori infection and pepsinogen levels of serum in gastric cancer patients.
H. pylori (+) (n = 311)
H. pylori (-) (n = 139)
P value
PGI(μg/L)
92.2 (53.0-145.3)
94.4 (38.9-148.8)
0.96
PG II (μg/L)
18.4 (10.4-30.0)
13.3 (7.7-22.5)
0.01
PGI/PGII
5.1 (3.5-7.2)
6.2 (3.5-10.0)
0.01
Table 4 Gastric cancer stages and serum pepsinogen levels.
TNM stage (n)
PGI(μg/L)
PG II (μg/L)
PGI/PG II
I(64)
101.4 (76.3-147.3)
18.4 (12.1-27.2)
6.3 (4.5-8.4)
II(182)
96.3 (44.7-167.2)
16.3 (9.3-27.1)
5.5 (4.0-8.2)
III (145)
85.8 (43.4-133.3)
15.4 (8.8-28.7)
4.9 (2.8-7.5)
IV (59)
71.5 (35.7-137.0)
13.1 (6.7-13.1)
5.1 (3.1-8.1)
P value
0.02
0.44
0.09
DISCUSSION
Serum PGIis produced by chief cells and mucous neck cells of gastric fundic glands, while PG II is produced by those cells and also by pyloric glands and Brunner’s glands[11]. Atrophic gastritis, characterized by loss of the specialized cells and glands in the stomach, is considered as a gastric cancer precursor lesion[12]. Serum PG levels, pepsin precursors, reflect the functional and morphological status of the gastric mucosa. It is widely accepted in gastric H. pylori infection that the fundic gland mucosa and PGIlevels gradually decrease, whereas PG II levels remain constant[13,14]. Consequently, a stepwise reduction of the PGI/PG II ratio is closely linked to progression of atrophic gastritis. However, PG II is considered to be a subordinate marker in clinical diagnosis. In fact, PG II, a mature marker of gastric epithelia, reflects the physiological or pathophysiological functions of the gastric system[15,16].
Gastritis is more prevalent and severe in Japan, with more corpus predominant atrophy and intestinal metaplasia[17-19]. PGI≤ 70 ng/mL and PGI/PG II ratio ≤ 3.0 have been used for the diagnosis of extensive atrophic gastritis with sensitivity of 80% and specificity of 70%[20]. In contrast, our study showed a low incidence of gastric mucosal atrophy in the Chinese population. Inconsistency between studies may be due to different ethnic groups with different genetic backgrounds, different ELISA kits, and different cutoff values used for assessment of gastric mucosal atrophy[21]. We used PGI≤ 82.3 μg/L and PGI/PG II ratio ≤ 6.05 according to the study for diagnosis of atrophic gastritis in the Chinese population[10]. For reference, the cut-off points of PGIand PGI/PG II ratio were calculated using receiver operator characteristic (ROC) curves. For patients with atrophic gastritis, the area under the ROC for PGIwas 0.878 (95%CI: 0.837-0.919) and the best cutoff value was 82.30 μg/L (sensitivity 85.9%, specificity 75.1%). The area under the ROC for PGI/PG II ratio was 0.819 (95%CI: 0.767-0.871) and the best cutoff value was 6.05 (sensitivity 78.3%, specificity 71.6%)[10]. The limitation of our study was that it could not determine the area under the curve via numerical integration of ROC curves, because we did not administer a further validity study. In our study, we found that serum PGIlevels were significantly decreased in the gastric atrophy group, but no difference was found between the gastric cancer and control groups. Thus, it is considered that serum PGIlevels represent gastric atrophy but not gastric cancer. The reason was that the prevalence of gastric atrophy was relatively low in our gastric cancer group compared with that in Japan. In Japan, the incidence of gastritis was higher than in other countries, and it was characterized by heavy predominant atrophy and intestinal metaplasia in the corpus of the stomach. Compared to the findings in Japan, our study showed a lower incidence of gastric mucosal atrophy. This may be due to differences in the research populations and their genetic backgrounds, even though the same H. pylori infection can lead to differences in severity of gastric atrophy[22-24]. Other factors such as the use of proton pump inhibitors (PPIs) may also influence the incidence of gastric atrophy. However, a history of using PPIs and lifestyle were not investigated in this study. A further prospective control study is needed. PG II levels were significantly increased in patients with gastric atrophy and gastric cancer, especially in H. pylori (+) gastric cancer, resulting in a reduction in PGI/PG II ratio, which was consistent with a previous study[6].
A few studies have investigated PG II serum level as an independent biomarker with potential clinical applications[25]. Higher PG II expression has been demonstrated in patients with gastric ulcers, suggesting that PG II level reflects chronic inflammation in H. pylori-related chronic gastritis[26-28]. Another study has shown that insertion/deletion polymorphisms of the PG II gene are highly associated with genetic predisposition to gastric cancer in the carriers[16]. Our study demonstrated that chronic H. pylori infection is at a high level in the Chinese population. The overall H. pylori (+) rate in patients with gastric carcinoma was 78.6% in young patients (< 45 years), which was significantly higher than that in the control group (51%). Active gastritis caused by H. pylori infection and chronic inflammation resulted in elevated PG II levels in the gastric cancer group.
We also found that serum PGIlevel was significantly lower in patients with stage III and IV tumors, compared to those with stageIand II tumors. The mechanism is unclear but it may be associated with gastric mucosal atrophy gradually increasing with advancing gastric cancer.
We demonstrated that serum PG II level significantly increased in Chinese patients with H. pylori-infected gastric cancer, indicating that PG II can be used as an independent diagnostic marker for gastric cancer. It is cost-effective to screen PG II in countries with a high incidence of gastric cancer, compared with the high cost of endoscopy. Further studies on normal ranges of PG II and its changes in gastric diseases may elucidate its physiological and pathological functions.
In conclusion, PG II can be used as an independent diagnostic marker for gastrointestinal cancer[29-31].
ACKNOWLEDGMENTS
The authors would like to thank everybody who participated in this study; particularly Mr. Chang-Song Guo and Ms. Ying Song for their technical support.
COMMENTS
Background
Early detection is an important way to reduce mortality of gastric cancer. Measurement of serum pepsinogen (PG) is a popular non-invasive serological screening test for gastric cancer.
Research frontiers
Research has shown that serum-PG testing, based on the combination of the measurement of serum PGIconcentration and the PGI/PG II ratio, is a good predictor of atrophic gastritis and gastric cancer development.
Innovations and breakthroughs
PG II has been as considered a subordinate marker in clinical diagnosis. In this study, we demonstrated that the serum PG II level significantly increased in Helicobacter pylori-infected gastric cancer in the Chinese population, indicating that PG II can be used as an independent diagnostic marker for gastric cancer.
Applications
Serum PG II level measure is a good method for screening patients with gastric cancer. It is very cost-effective to screen PG II in countries with high incidences of gastric cancer, compared with the high cost of endoscopy.
Terminology
PGs are inactive proenzymes for the specific digestive enzyme, pepsin, originating from the gastric mucosa, and can be classified into PGIand PG II.
Peer review
The authors performed a clinical epidemiological study and evaluated the possibility and significance of PG II in serum and PGI/PG II ratio as the diagnostic markers for Chinese patients with gastric cancer and gastric atrophy. They concluded that serum level of PG II could be a useful diagnostic marker for patients with gastric cancer.
Footnotes
Peer reviewers: Takaaki Arigami, MD, PhD, Department of Surgical Oncology and Digestive Surgery, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 891-0175, Japan; Guanglin Cui, MD, PhD, Laboratory of Gastroenterology, Institute of Clinical Medicine, University of Tromso, N-9037 Tromso, Norway
S- Editor Song XX L- Editor Kerr C E- Editor Li JY
Abnet CC, Zheng W, Ye W, Kamangar F, Ji BT, Persson C, Yang G, Li HL, Rothman N, Shu XO. Plasma pepsinogens, antibodies against Helicobacter pylori, and risk of gastric cancer in the Shanghai Women's Health Study Cohort.Br J Cancer. 2011;104:1511-1516.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 29][Cited by in F6Publishing: 34][Article Influence: 2.6][Reference Citation Analysis (0)]
Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Shakeri R, Persson EC, Islami F, Kamangar F, Abnet CC, Boffetta P, Engstrand L. Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis.PLoS One. 2011;6:e26957.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 37][Cited by in F6Publishing: 42][Article Influence: 3.2][Reference Citation Analysis (0)]
Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, Liu B, Fan JH, Abnet CC. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.Gut. 2009;58:636-642.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 57][Cited by in F6Publishing: 68][Article Influence: 4.5][Reference Citation Analysis (0)]
Di Mario F, Cavallaro LG, Moussa AM, Caruana P, Merli R, Maini A, Bertolini S, Dal Bó N, Rugge M, Cavestro GM. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium.Dig Dis Sci. 2006;51:1791-1795.
[PubMed] [DOI][Cited in This Article: ]
Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, Xing X, Wang J, Du Z, Misumi J. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community.Int J Cancer. 2012;130:1614-1619.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 24][Cited by in F6Publishing: 29][Article Influence: 2.2][Reference Citation Analysis (0)]
